Involvement of the endogenous cannabinoid 2 ligand 2-arachidonyl glycerol in allergic inflammation.
BACKGROUND
Cannabinoid (CB) 2 is expressed on immune and inflammatory cells. Identification of 2-arachidonyl glycerol (2-AG) and anandamide as endogenous CB2 ligands has allowed investigations of the roles of CB2 and its endogenous ligand system in inflammatory cells. However, the roles of this receptor-ligand system in inflammatory and allergic immune responses in vivo have not been fully elucidated.


METHODS
Two mouse allergy models, namely ear dermatitis induced by 2,4-dinitrofluorobenzene and allergic bronchitis induced by ovalbumin, were analyzed for 2-AG amounts in allergic tissues, with reference to allergic and inflammatory symptoms. To investigate the gene expression via CB2 in inflammatory cells, human promyelocytic HL-60 cells were stimulated by the CB2 ligand 2-AG ether and analyzed using a DNA microarray.


RESULTS
In the ear dermatitis model, the 2-AG amount increased upon serial 2,4-dinitrofluorobenzene challenges and was correlated with ear weight gain. The increased ear thickness in this allergy model was clearly suppressed in CB2 knockout mice, suggesting that the generated endogenous CB2 ligands induce ear thickness through aberrant inflammatory responses and remodeling mediated via CB2. In the allergic bronchitis model, the 2-AG level in bronchoalveolar lavage was increased and sustained during the elevation of inflammatory cell infiltration. The DNA microarray analysis of human HL-60 cells revealed that 2-AG ether induced expressions of not only inflammatory chemokines/cytokines but also of cell growth factors.


CONCLUSIONS
Our data strongly suggest that endogenous CB2 ligands upregulated upon disease progression in allergic models are involved in aberrant alterations of both inflammatory responses and tissue cell growth.
Pharmaceutical Frontier Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., Kanagawa, Japan.
Takayuki
T
Mimura
Saori
S
Oka
Hiroyuki
H
Koshimoto
Yoshifumi
Y
Ueda
Yoshihiro
Y
Watanabe
Takayuki
T
Sugiura
D000818:Animals; D001095:Arachidonic Acids / Q000276:immunology* / Q000378:metabolism*; D001991:Bronchitis / Q000276:immunology / Q000378:metabolism; D002186:Cannabinoids / Q000378:metabolism*; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D016207:Cytokines / Q000235:genetics / Q000378:metabolism; D017449:Dermatitis, Allergic Contact / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D004195:Disease Models, Animal; D063388:Endocannabinoids / Q000276:immunology* / Q000378:metabolism*; D005260:Female; D015870:Gene Expression; D005989:Glycerides / Q000276:immunology* / Q000378:metabolism*; D006133:Growth Substances / Q000235:genetics / Q000378:metabolism; D018922:HL-60 Cells; D006801:Humans; D006967:Hypersensitivity / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D007249:Inflammation / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D043885:Receptor, Cannabinoid, CB2 / Q000172:deficiency / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*
D001095:Arachidonic Acids; D002186:Cannabinoids; D018925:Chemokines; C571431:Cnr2 protein, mouse; D016207:Cytokines; D063388:Endocannabinoids; D005989:Glycerides; D006133:Growth Substances; D008024:Ligands; D043885:Receptor, Cannabinoid, CB2; C094503:glyceryl 2-arachidonate